Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Vosoritide

Vosoritide (Voxzogo)

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 12 September 2026

Vosoritide is a real, well-trialed, currently approved drug — a C-type natriuretic peptide analog cleared for achondroplasia in 2021 and expanded to children under 5 in 2023 — a genuinely different peptide family from anything else on this site. The trial evidence for its approved endpoint, growth velocity, is solid. Whether increasing growth velocity is itself the right goal is a real, live, unresolved debate within the achondroplasia and disability community — worth knowing before treating this as an uncomplicated medical win.

On this page
  1. What it is, and its real approval
  2. The pivotal trial evidence
  3. The 2023 expansion to children under 5
  4. A real, unresolved debate about the goal itself

In brief

Should you care? Yes — this is a different peptide family entirely (a natriuretic peptide analog, not a growth-hormone-axis or GLP-1 compound), with real trial data and a real, current, still-expanding FDA approval.

The short version

  • FDA accelerated approval (Voxzogo, 19 November 2021) for children 5+ with achondroplasia and open growth plates.
  • A real, randomized, placebo-controlled Phase 3 trial (121 children) backs the approval.
  • Expanded in 2023 to children under 5; a real, ongoing debate exists within the achondroplasia community over whether growth velocity is the right thing to be treating.

What it is, and its real approval

Vosoritide is an analog of C-type natriuretic peptide (CNP) developed by BioMarin. It works by activating the NPR-B receptor, which counteracts the overactive FGFR3 signaling that causes achondroplasia — the most common form of disproportionate short stature, caused by a specific, well-characterized genetic mutation. FDA granted accelerated approval to Voxzogo on 19 November 2021, for children 5 years and older with achondroplasia and open growth plates, to increase linear growth — the first approved treatment for the condition.

The pivotal trial evidence

The pivotal trial (Savarirayan et al., Lancet 2020;396(10252):684-692, PMID 32891212) randomized 121 children with achondroplasia to vosoritide or placebo for 52 weeks, finding a statistically significant improvement in annualized growth velocity over placebo — a real, controlled, randomized result. (A subsequent "Department of Error" notice for this paper corrected a co-author's name spelling; it did not change any trial data or conclusions.)

The 2023 expansion to children under 5

In October 2023, FDA approved a supplemental application extending Voxzogo to children under 5 with open growth plates — effectively all pediatric ages — based on a separate randomized, placebo-controlled Phase 2 trial in that younger age group. This is a real, current, still-active approval program; BioMarin continues long-term extension studies to track outcomes.

A surrogate endpoint, and a real conflict-of-interest wrinkle

Vosoritide's approval rests on annualized growth velocity — a surrogate/biomarker endpoint, not a directly measured improvement in mobility, joint complications, spinal stenosis risk, or quality of life, which is why it went through the accelerated approval pathway pending confirmatory data. Separately, a set of international clinical-practice consensus guidelines for vosoritide use disclosed that a majority of the guideline-author group had financial ties to BioMarin — a real, disclosed conflict worth knowing when reading clinical guidance on how to use this specific drug.

A real, unresolved debate about the goal itself

Little People of America, the largest US advocacy organization for people with short stature including achondroplasia, has published a position statement describing vosoritide's focus on growth velocity as, in effect, treating a societal problem with a pharmaceutical solution — drawing on the social model of disability, which locates disability in environmental and social barriers rather than in physical stature itself. This is a real, live, values-based disagreement within the patient community, not a fringe objection, and it sits alongside — not against — the genuine trial evidence that vosoritide does measurably increase growth velocity. Whether that's the right thing to be optimizing for is a question this site can't resolve for you, but it's a real part of the honest picture.

References

  1. FDA accelerated approval of Voxzogo (vosoritide), 19 November 2021, for children 5+ with achondroplasia and open growth plates.
  2. Savarirayan R, Tofts L, Irving M, et al., "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial," Lancet 2020;396(10252):684-692, PMID 32891212; a subsequent Department of Error notice (PMID 33038967) corrected a co-author name spelling only.
  3. FDA approval of expanded Voxzogo indication for children under 5 with achondroplasia, October 2023.
  4. Little People of America position statement on vosoritide, and international consensus guidelines on vosoritide implementation disclosing majority BioMarin financial ties among guideline authors.